PharmacyChain
Search documents
Wellgistics Health Reminds Shareholders of December 19, 2025 Record Date for Dream Bowl 2026 Meme Coin Tokens
Accessnewswire· 2025-12-17 12:40
TAMPA, FL / ACCESS Newswire / December 17, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx â"¢ into its patented blockchain-enabled smart contracts platform PharmacyChainâ"¢, today reminded shareholders of the December 19, 2025 record date (the "Record Date") to receive Dream Bowl 2026 Meme Coin ("Dream Bowl") tokens. All eligible record holders of Wellg ...
This Penny Stock Just Tripled on Blockchain News. Should You Buy Shares Now?
Yahoo Finance· 2025-10-24 18:39
Core Insights - Wellgistics (WGRX) shares surged over 300% following the announcement of a non-binding letter of intent with Datavault (DVLT) for a new initiative called "PharmacyChain" [1] - The PharmacyChain initiative aims to utilize blockchain technology to digitize prescription tracking, enhancing transparency and efficiency in pharmacy operations [3][4] Company Developments - The partnership with Datavault is expected to lend credibility to Wellgistics' technology rollout and indicates a shift from being a traditional distributor to a health-tech innovator [4] - Wellgistics has proposed a revenue-sharing model with pharmacies, potentially creating a recurring income stream for the company [4] Market Context - Despite the recent surge, WGRX shares are still down nearly 85% from their six-month high reached in May [2] - The PharmacyChain initiative is currently in an exploratory phase, with no binding commitments or detailed financial disclosures, which raises questions about its future commercial success [6] Investment Considerations - Wellgistics is characterized as a micro-cap company with minimal revenue and no history of sustained profitability, making it a risky investment [5] - The stock does not currently receive coverage from Wall Street analysts, which may deter potential investors [8]